Regeneron Pharmaceuticals, Inc. Free Cash Flow 2008–2025
Regeneron Pharmaceuticals, Inc. reported $4.08B of free cash flow for fiscal 2025. That was 11.3% higher than fiscal 2024. Compared with fiscal 2020, the change was +103.7%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $4.08B | +11.3% |
| FY 2024 | $3.66B | -5.4% |
| FY 2023 | $3.88B | -12.4% |
| FY 2022 | $4.42B | -32.2% |
| FY 2021 | $6.53B | +225.9% |
| FY 2020 | $2.00B | +0.2% |
| FY 2019 | $2.00B | +10.4% |
| FY 2018 | $1.81B | +75.2% |
| FY 2017 | $1.03B | +6.2% |
| FY 2016 | $974.00M | +49.2% |
| FY 2015 | $652.85M | +55.7% |
| FY 2014 | $419.43M | -3.0% |
| FY 2013 | $432.27M | +448.7% |
| FY 2012 | $-123.95M | +37.7% |
| FY 2011 | $-198.90M | -42490.8% |
| FY 2010 | $-467,000 | +99.7% |
| FY 2009 | $-167.25M | -34.9% |
| FY 2008 | $-123.94M | — |
Source: Regeneron Pharmaceuticals, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open REGN 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Regeneron Pharmaceuticals, Inc. reported $4.08B of free cash flow for fiscal 2025. That was 11.3% higher than fiscal 2024. Compared with fiscal 2020, the change was +103.7%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Regeneron Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeRegeneron Pharmaceuticals, Inc. — frequently asked questions
What is Regeneron Pharmaceuticals, Inc.'s free cash flow?
Regeneron Pharmaceuticals, Inc. (REGN) reported free cash flow of $4.08B for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Regeneron Pharmaceuticals, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.